Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Retinoic acid receptor alpha, beta, and gamma are members of the nuclear receptor superfamily, encoded by distinct genes (RARA, RARB, and RARG). These receptors are activated by retinoic acid, a metabolite of vitamin A, and regulate gene transcription involved in development, differentiation, cell proliferation, and apoptosis. Upon ligand binding, RARs form heterodimers with retinoid X receptors (RXRs), recruit coactivators, and drive expression of genes with retinoic acid response elements (RAREs). Expression and function of each RAR subtype can be tissue-specific, and they play both shared and unique roles in embryonic and adult physiology, disease processes, and as drug targets for retinoids (especially in cancer and dermatology). Resistance and toxicity are clinical challenges in retinoid-based therapies.
Ligand binding to RAR causes dissociation of corepressors (NCOR, SMRT), recruitment of coactivators, and transcriptional activation of target genes. Drives gene expression involved in cell cycle regulation, differentiation, and apoptosis
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinoic acid receptor alpha, beta, gamma (RAR-α, RAR-β, RAR-γ).